Quantcast

Latest Sunitinib Stories

2010-10-25 07:00:00

BURLINGTON, Mass., Oct. 25 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of renal cell carcinoma (RCC), the majority of surveyed European oncologists who favor Pfizer's Sutent indicate that they would switch to an emerging therapy only if it extended progression-free survival (PFS) by at least an additional two to three months, assuming the agent's safety and tolerability...

2010-10-12 17:57:41

New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients. Dr Yohann Loriot and Dr Thomas Bessede from Institut...

2010-10-07 05:00:00

NEW YORK, Oct. 7 /PRNewswire-FirstCall/ -- Pfizer Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers. These results will be presented at the 35(th) European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO ) "Pfizer...

2010-10-01 07:00:00

CHICAGO, Oct. 1 /PRNewswire/ -- Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial. The interim data demonstrated positive median PFS results in unfavorable risk, newly diagnosed, metastatic RCC (mRCC) patients. The median PFS was 14.9 months for intermediate risk and six months for poor...

2010-09-27 16:01:00

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT® (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of sunitinib with...

2010-09-24 07:00:00

DURHAM, N.C., Sept. 24 /PRNewswire/ -- Argos Therapeutics today announced that results from its Arcelis(TM) immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago. The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC. Post-nephrectomy, subjects received sunitinib and then concomitant...

2010-08-23 16:01:00

NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE :PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or...

2010-07-01 00:25:00

EAST HANOVER, N.J., July 1 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that results of a Phase III study show Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival, or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET). The study, RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors), was presented at the 12th World...

2010-06-29 08:00:00

WALTHAM, Mass., June 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2019, robust 4.1 percent annual growth in the renal cell carcinoma drug market will be driven primarily by the uptake of GlaxoSmithKline's Votrient/Patorma, the launches of premium-priced emerging therapies and an increase in diagnosed incidence and treatment rates. The Pharmacor 2010 findings from the topic...

2010-06-07 14:01:57

Georgetown researcher says it is important to expand access for these patients to NCI-sponsored clinical trials Preliminary findings from a unique study with sunitinib suggest that it might be possible to tweak the dosage of chemotherapy drugs used to treat HIV-positive cancer patients to achieve therapeutic benefit. Given the type of drug cocktail patients use to treat their HIV, much more or considerably less chemotherapy may be warranted, say the researchers, part of the NCI-supported AIDS...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related